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Inhibition of Mycobacterium 
tuberculosis dihydrodipicolinate 
synthase by alpha-ketopimelic acid 
and its other structural analogues
Priyanka Shrivastava1,2, Vikas Navratna3, Yumnam Silla4, Rikeshwer P. Dewangan1, 
Atreyi Pramanik1, Sarika Chaudhary1, GeethaVani Rayasam5, Anuradha Kumar5, 
Balasubramanian Gopal3 & Srinivasan Ramachandran1,2
The Mycobacterium tuberculosis dihydrodipicolinate synthase (Mtb-dapA) is an essential gene. Mtb-
DapA catalyzes the aldol condensation between pyruvate and L-aspartate-beta-semialdehyde (ASA) 
to yield dihydrodipicolinate. In this work we tested the inhibitory effects of structural analogues 
of pyruvate on recombinant Mtb-DapA (Mtb-rDapA) using a coupled assay with recombinant 
dihydrodipicolinate reductase (Mtb-rDapB). Alpha-ketopimelic acid (α-KPA) showed maximum 
inhibition of 88% and IC50 of 21 μM in the presence of pyruvate (500 μM) and ASA (400 μM). 
Competition experiments with pyruvate and ASA revealed competition of α-KPA with pyruvate. Liquid 
chromatography-mass spectrometry (LC-MS) data with multiple reaction monitoring (MRM) showed 
that the relative abundance peak of final product, 2,3,4,5-tetrahydrodipicolinate, was decreased by 
50%. Thermal shift assays showed 1 °C Tm shift of Mtb-rDapA upon binding α-KPA. The 2.4 Å crystal 
structure of Mtb-rDapA-α-KPA complex showed the interaction of critical residues at the active site 
with α-KPA. Molecular dynamics simulations over 500 ns of pyruvate docked to Mtb-DapA and of 
α-KPA-bound Mtb-rDapA revealed formation of hydrogen bonds with pyruvate throughout in contrast 
to α-KPA. Molecular descriptors analysis showed that ligands with polar surface area of 91.7 Å2 are 
likely inhibitors. In summary, α-hydroxypimelic acid and other analogues could be explored further as 
inhibitors of Mtb-DapA.
Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) is a leading killer among infectious diseases 
worldwide. TB alone accounts for 1.5 million deaths per year1. The principal route of infection is through inha-
lation of aerosols containing Mtb bacteria thereby causing pulmonary TB. Mtb also colonizes other tissues of the 
body causing extra-pulmonary TB. Further, Mtb, including its multidrug and extensively drug-resistant strains, 
transforms into a persistent state and can remain for long times in the host2.
The cell wall of Mtb is particularly rigid, rich in mycolic acids covalently linked to the arabinogalactan layer 
and cross-linked by the peptidoglycan layer3. Therefore the enzymes of the cell wall biosynthesis and maintenance 
pathways constitute promising targets for the identification of new antitubercular therapeutics. The Mtb dihy-
drodipicolinate synthase (Mtb-DapA) is one such target4.
The synthesis of lysine and meso-diaminopimelate (M-DAP) in mycobacteria are accomplished through the diami-
nopimelate (DAP) pathway5. Both lysine and M-DAP are essential for bacterial growth and survival6. Lysine is needed 
for protein biosynthesis. M-DAP is an important component for crosslinks in the peptidoglycan layer, which has been 
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implicated as a potential virulence factor7. Inhibitors of enzymes in the DAP pathway could be considered for develop-
ment of new antibacterial drugs because this pathway is indispensable for bacteria and is absent in humans5.
The DAP pathway (Supplementary Figure S1) begins with phosphorylation of L-aspartate to 
L-β -aspartyl-4-phosphate catalyzed by aspartokinase. Next, L-β -aspartyl-4-phosphate is reduced to 
L-aspartate-beta-semialdehyde (ASA) catalyzed by aspartate semialdehyde dehydrogenase. This is followed 
by a Schiff base formation with pyruvate and addition of ASA to form (4S)-4-hydroxy-2,3,4,5-tetrahydro-
(2S)-dipicolinate (HTPA) catalyzed by dihydrodipicolinate synthase (Mtb-DapA)8 (Supplementary Figure S2). 
Next, HTPA is reduced to 2,3,4,5-tetrahydrodipicolinic acid (THDP) catalyzed by dihydrodipicolinate reductase 
(Mtb-DapB) using NADPH9 as an electron donor. In mycobacteria, THDP undergoes a series of biochemical 
transformations to yield meso-diaminopimelate (M-DAP)10.
The crystal structures of Mtb-DapA11 and its homologues from Escherichia coli12, Nicotiana sylvestris13, 
Thermotoga maritima14, Clostridium botulinum15, Corynebacterium glutamicum16, Bacillus anthracis17 and 
Staphylococcus aureus18 have been determined. Mtb-DapA belongs to the subfamily of N-acetylneuraminate lyase 
(α /β )8 proteins. It contains an N-terminal (α /β )8 TIM barrel catalytic core and an α -helical C-terminal domain19. 
The active site of the enzyme is located at the center of the monomer towards the C-terminal end of the TIM bar-
rel. The active site residues Thr54, Thr55, Tyr143, Arg148 and Lys171 of Mtb-DapA are largely conserved among 
its homologues11,20. The Mtb-DapA structure, determined at 2.28 Å resolution11, revealed a homotetramer state, 
a dimer of tight dimers. The ping-pong reaction mechanism of DapA in Escherichia coli is well characterized21. 
Pyruvic acid forms a Schiff base upon condensation with ε -amino group of the active site Lys161 of E. coli DapA, 
and ASA binds to Arg138 located at the entrance of the active site via hydrogen bonding22. The aldol condensa-
tion between the pyruvate-bound enzyme and ASA is facilitated by a proton relay motif comprised of two tyros-
ine residues Tyr107 and Tyr133 and a threonine residue Thr44 to yield DHDP23. The corresponding amino acid 
residues in Mtb-DapA are Lys171, Arg148, Tyr117, Tyr143 and Thr54.
Transposon mutagenesis experiments in M. tuberculosis showed that the genes of the DAP pathway, namely, 
aspartokinase (ask), aspartate-semialdehyde dehydrogenase (asd), dihydrodipicolinate synthase (dapA), tet-
rahydrodipicolinate N-succinyltransferase (dapD), N-succinyldiaminopimelate aminotransferase (dapC), 
succinyl-diaminopimelate desuccinylase (dapE), diaminopimelate epimerase (dapF), and diaminopimelate 
decarboxylase (lysA) are all essential for mycobacterial growth24–26 except for dapB (dihydrodipicolinate reduc-
tase). The dapB mutant grows, albeit slowly27,28. In a recent study, dapF was found to be co-expressed with 
other essential genes including Rv1611 (tryptophan synthase C), Rv1308 (ATP synthase A), Rv2152c (murC, 
UDP-N-acetylmuramoyl-L-alanine synthetase), and Rv3028c (etpfA, electron transfer flavoprotein alpha subunit) 
in in vitro growth conditions29. Although the murC and dapF genes are located 628.28 kb apart in the genome of 
Mtb, a strong positive co-expression of dapF with the peptidoglycan pathway gene (murC) suggests a co-regulated 
relationship between the DAP pathway and the peptidoglycan biosynthesis pathway.
Mtb-DapA is a putative drug target for which no potent inhibitor is reported. Couper et al.30 tested a series 
of derivatives of piperidine and pyridine-2,6-dicarboxylate against the Escherichia coli DapA, including N-oxide 
of dipicolinic acid and di-imidate of dimethyl pyridine-2,6-dicarboxylate, each with an IC50 value of 0.2 mM30. 
Karsten et al.21 reported a few competitive inhibitors against E. coli DapA, which are structural analogues of 
pyruvate, namely, 3-fluoropyruvate (Ki = 0.22 mM), α -ketobutyrate (Ki = 0.83 mM), α -ketovalerate (Ki = 0.7 mM) 
and glyoxylate (Ki = 0.016 mM)21. Boughton et al.31 reported 8 conformationally constrained diketopimelic acid 
analogues as inhibitors and obtained inhibition in the range of 2–49% at 5 mM concentration of each inhibitor31. 
Turner et al.32 designed inhibitors based on oxygen functionality at the C4 position (–OH or –C= O) which mim-
ics acyclic enzyme-bound intermediate 4-hydroxytetrahydrodipicolinate (HTHDP), but they showed only 50% 
inhibition with 0.5–50 mM concentrations32.
In this work, we tested several pyruvate analogues and investigated the mechanism of inhibition of Mtb-DapA 
by α –ketopimelic acid. In addition, we also describe the co-crystal structure of Mtb-DapA with α -ketopimelic 
acid. Our work could serve as a foundation for developing new drug-like inhibitors of Mtb-DapA.
Results
Screening of pyruvate analogues. We determined the Michaelis constant, Km, of the recombinant Mtb-
DapA (Mtb-rDapA) for pyruvate and ASA to be 148.8 μ M and 388 μ M respectively, which are very close to those 
reported previously11. We carried out all assays at fixed concentrations of the substrates, pyruvate and ASA at 
500 μ M and 400 μ M, respectively (Supplementary Figure S3A,B).
The results of kinetic experiments using a coupled assay with various pyruvate analogues are shown in Table 1. 
The proportion of inhibition measured at different concentrations of the analogues showed that the IC50 for 
α -KPA was 21 μ M and the inhibition constant Ki was 32.5 μ M at 500 μ M pyruvate and 400 μ M ASA (Fig. 1A). 
Among the structurally similar compounds (alpha-keto adipicacid, alpha-ketoglutaric acid and pimelic acid) 
with saturated hydrocarbon chains, only α -KPA could achieve maximal inhibition of 88%. Alpha-ketoadipic 
acid showed moderate inhibition at 40% and alpha-ketoglutaric acid showed low inhibition at 15% (Fig. 1A). 
Interestingly, pimelic acid, which is devoid of the α -keto group but retains the same carbon chain length, did not 
exhibit inhibition even at millimolar concentrations (Fig. 1A). The methyl este,r methyl 3-oxohexanoate, with 
the keto group shifted by one carbon also did not show any inhibition (Supplementary Figure S4A). These results 
highlight the critical importance of the α -keto group and the length of the aliphatic carbon chain. We also tested 
compounds with aromatic groups, namely, benzoic acid, fusaric acid, p-amino benzoic acid, p-aminosalicylic 
acid, and phenoxyacetic acid (Supplementary Figure S4B–F). None of these showed inhibition.
Shortening the aliphatic chain of α -KPA by even one carbon had a pronounced effect, with a 50% loss of 
inhibition. Further chain shortening resulted in further loss of inhibition to 15%. It is interesting to note that the 
three compounds with any observable inhibitory activity had the highest topological polar surface area 91.7 Å2 
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S. No IUPAC NAME Structure
Molecular 
weight (Da)
Maximal 
Inhibition 
(%)
Topological 
Polar Surface 
Area(Å2)
Molecular 
Formula
1 2-oxoheptanedioic acid (α –KPA) 174.15 88 91.7 C7H10O5
2 2-oxohexanedioic acid 160.12 40 91.7 C6H10O5
3 2-oxopentanedioic acid 146.11 15 91.7 C5H10O5
4 heptanedioic acid 160.17 10 74.6 C7H10O4
5 Benzoic acid 122.12 2 37.3 C7H6O2
6 p-amino benzoic acid 137.13 8 63.3 C7H7NO2
7 Methyl 3-oxohexanoate 144.16 5 43.4 C7H12O3
Continued
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S. No IUPAC NAME Structure
Molecular 
weight (Da)
Maximal 
Inhibition 
(%)
Topological 
Polar Surface 
Area(Å2)
Molecular 
Formula
8 4-amino-2-hydroxy-benzoic acid 153.13 4 83.6 C14H14N2O6
9 2-phenoxyacetic acid 152.14 4 46.5 C8H8O3
10 5-butylpyridine-2-carboxylic acid 179.21 5 50.2 C10H13NO2
11 hydroxyheptanedioic acid 176.17 74 94.83 C7H12O5
12 Methyl-oxo-ureidopentanoate 188.18 65 98.49 C7H12N2O4
13 5-(Carbamoylthio)pentanoic acid 177.22 65 80.39 C6H11NO3S
14 amino-oxobutyl-methyl-amino-oxoacetic acid 188.18 44 94.91 C7H12N2O4
15 methyl-ethoxy-methyl-oxoacetamido-butanoate 231.25 42 72.91 C10H17NO5
16 oxo-ureidopentanoic acid 174 40 109.4 C6H10N2O4
17 amino-oxobutyl-methyloxalamide 187.2 40 106.49 C7H13N3O3
Continued
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S. No IUPAC NAME Structure
Molecular 
weight (Da)
Maximal 
Inhibition 
(%)
Topological 
Polar Surface 
Area(Å2)
Molecular 
Formula
18 carboxy-methylformamido-butanoic acid 189.17 39 94.91 C7H11NO5
19 methyl-trioxoimidazolidin –butanoate 214.18 38 121.6 C8H10N2O5
20 Ethoxy-dioxoheptanoic acid 202.21 35 94.83 C9H14O5
21 methyl-oxo-tetrazol-hexanoate 212 35 114.62 C8H12N4O3
22 Methyl-amino-oxoacetyl benzoate 207.19 35 100.62 C10H9NO4
23 Carboxy-hydroxy-methyl benzoic acid 196.16 35 94.83 C9H8O5
24 Hydroxy-methoxycarbonyl pheny acetic acid 210.19 35 91.67 C10H10O5
25 Ethyl-amino-oxobutyl-methyl-amino-oxoacetate 216.24 35 89.70 C9H16N2O4
26 amino-oxoacetyl-benzoic acid 183 34 97.46 C9H7NO4
27 ethyl-carbamoylthio-pentanoate 205.27 34 126.5 C8H15NO3S
Continued
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S. No IUPAC NAME Structure
Molecular 
weight (Da)
Maximal 
Inhibition 
(%)
Topological 
Polar Surface 
Area(Å2)
Molecular 
Formula
28 Ethyl 4-((2-amino-2-oxoethyl)sulfinyl)butanoate 221.27 31 86.18 C8H15NO4S
29 methoxycarbonyl-phenyl-oxoacetic acid 208.17 29 97.46 C10H8O5
30 4-((2-amino-2-oxoethyl)sulfonyl)butanoic acid 209.22 29 114.5 C6H11NO5S
31 Methyl 7-amino-6-hydroxy-7-oxoheptanoate 189.21 28 94.83 C8H15NO4
32 methyl 7-amino-6,7-dioxoheptanoate 187.2 24 86.46 C8H13NO4
33 carboxycarbonyl-benzoic acid 194 22 91.67 C9H6O5
34 Ethyl 4-((2-amino-2-oxoethyl)thio)butanoate 205.27 21 90.06 C8H15NO3S
35 2-Hydroxyheptanediamide 174.2 21 100.7 C7H14N2O3
36 4-(2,4,5-Trioxoimidazolidin-1-yl)butanoic acid 200.15 21 92.70 C7H8N2O5
37 2-(4-Carbamoylphenyl)-2-oxoacetic acid 193.16 15 97.46 C9H7NO4
Continued
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S. No IUPAC NAME Structure
Molecular 
weight (Da)
Maximal 
Inhibition 
(%)
Topological 
Polar Surface 
Area(Å2)
Molecular 
Formula
38 4-((2-Amino-2-oxoethyl)thio)butanoic acid 177.22 15 80.39 C6H11NO3S
39 Ethyl 4-((2-amino-2-oxoethyl)sulfonyl)butanoate 237.27 12 114.5 C8H15NO5S
Table 1.  Pyruvate and α-KPA analogues tested for inhibition of Mtb-rDapA. Maximal inhibition is the 
highest inhibition achieved relative to that in absence of inhibitor by varying the concentration of the inhibitor 
at a given concentration of other substrates pyruvate 500 μ M and ASA 400 μ M.
Figure 1. (A) IC50 analysis of pyruvate analogues: The percentage of inhibition by each inhibitor relative to 
control (in absence of inhibitor) was determined using the coupled assay. The protein was pre-incubated with 
each compound for 5 min at various concentrations (0–1000 uM) before the assay. Triplicate measurements 
were taken at each time point and data were plotted with mean ± 1SD. (B) Competition analysis to infer the 
potential binding site of α-KPA: The competition experiments were conducted using the coupled assay after 
5 min pre-incubation across various concentrations of α -KPA. Substrates concentrations were held constant 
at 500 μ M of pyruvate and 400 μ M of ASA in assay mix. The Mtb-rDapA protein was pre-incubated with (a) α 
-KPA (0-1 mM), (b) α -KPA + pyruvate (500 μ M), (c) with α -KPA + ASA (400 μ M), and (d) pyruvate (500 μ M) 
before addition of other assay components. Each concentration point was measured at least in triplicate and 
data were plotted as mean ± 1SD.
Time (min) from start 0.17 mM 0.3 mM 1 mM 2 mM
10 21 21 21 61
20 21 21 21 61
30 21 21 21 71
40 31 31 31 81
50 41 41 41 91
60 51 51 51 101
Table 2.  IC50 of α-KPA. Inhibition of Mtb-rDapA in the presence of 400 μ M of ASA and variable 
concentrations of pyruvate.
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(Table 1) compared with rest. It is therefore probable that bulkier moieties (aromatic groups) and molecules with 
lower polar surface area for similar molecular weight may not be as inhibitors of Mtb-rDapA.
Structural analogues of α-KPA. We carried out a rational design approach for Mtb-DapA inhibitors 
based on the structure of α -KPA. α -KPA has two COOH groups and a keto group. We carried out a series of sub-
stitutions including substitution of the α -keto group with a hydroxyl, substitution of carboxyl groups with amide, 
and sulfoxides, sulfones, sulfonamides, imidazole and an azole group in the carbon skeleton. We have synthesized 
a total of 29 molecules. The TPSA varied from 72 Å2 to 126 Å2 and the molecular weights ranged from 174 Da to 
237 Da. Maximum inhibition at 250 μ M was in the range of 12–74% (Table 1). The α -hydroxyl pimelic acid was 
the strongest inhibitor, with a maximum inhibition 74% and IC50 of 31 μ M (Supplementary Figure S5A,B).
Competition at the active site. In order to identify the binding site of α -KPA, we determined the maximal 
inhibition of Mtb-rDapA in various conditions by pre-incubating Mtb-rDapA with (i) α -KPA, (ii) α -KPA and 
pyruvate, (iii) α -KPA and ASA, and (iv) pyruvate. We observed maximal inhibitions of 82%, 27%, 77%, and 49%, 
respectively (Fig. 1B). The IC50 of Mtb-rDapA pre-incubated with pyruvate was 160 μ M, which is nearly 8 fold 
higher compared to pre-incubation with α -KPA. These results suggest that α -KPA competes with pyruvate for a 
binding site in Mtb-rDapA.
In order to investigate the stability of the inhibition by α -KPA we carried out competition experiments with 
varied concentrations of pyruvate ranging from 0.17 to 2 mM and determined the IC50 values in each case over 
different time intervals. ASA was kept constant at 400 μ M. The results shown in Table 2 demonstrate that the 
IC50 of α -KPA increases from 21 μ M to 61 μ M at a high concentration 2 mM of pyruvate affirming that α -KPA 
is binding to the pyruvate binding site and is competing with it. Further, the gradual increases in IC50 with time 
at all the concentrations of pyruvate tested suggest that the binding of α -KPA to Mtb-rDapA is relatively stable.
Co-crystallization with α-KPA. The structure of Mtb-rDapA in complex with α -KPA was solved at 2.4 Å 
resolution (Fig. 2A). Except for the first three residues at the N-terminus and one residue at the C-terminus, the 
entire polypeptide could be modeled unambiguously into electron density (Fig. 2B). The N-terminal region is 
comprised of an (α /β )8 TIM barrel domain and the C-terminal region adopts a three- helical-bundle conforma-
tion. It is reported that in Mtb-DapA, Tyr143 and Thr54 of one monomer and Tyr117 of the adjacent monomer 
constitute the catalytic triad11. These residues juxtapose Lys171, a residue that forms Schiff base with pyruvate, 
and completes the active site boundary12,18. The bound substrate then undergoes aldol condensation with ASA 
aided by a proton relay motif comprising Thr54, Tyr117 and Tyr143 to generate DHDP23. The disruption of inter-
actions between these amino acids has been proposed as the basis for rational inhibitor design11.
The Mtb-rDapA-α -KPA complex structure comprises a monomer of the polypeptide in P42212 space group 
(Table 3). Hence, the residue Tyr117 that completes the catalytic triad could not be located closer to the active 
site. The structure reveals the presence of α -KPA at hydrogen bonding distance from the residues Thr54, Tyr143 
and Lys171. Alpha-KPA occupies the position of the substrate pyruvate and thus could prevent the formation of a 
Schiff base with pyruvate, which is the first step of the ping-pong reaction. In addition, α -KPA also forms hydro-
gen bonding interactions with Thr55, Arg148 and Gly194. The Mtb-DapA and Mtb-rDapA-α -KPA complexed 
Figure 2. Crystal structure of Mtb-rDapA α-ketopimelic acid complex. (A) A monomeric unit of Mtb-
rDapA in complex with α -ketopimelic acid. (B) An (mFo-DFc) electron density map at 1σ shows the presence 
of α -ketopimelic acid at the active site of Mtb-rDapA. Residues present at a distance of ca 3.5 Å from the bound 
inhibitor are displayed.
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structures superpose very well with an RMSD of 0.3 Å, indicating an apparent lack of conformational changes in 
the protein upon ligand binding.
Thermal shift assay. The binding of pyruvate and α -KPA to Mtb-rDapA was probed by performing a ther-
mal shift assay. Increase in the Tm of a protein in the presence of a ligand is often used as a measure of binding. 
Mtb-rDapA showed a Tm of 84.8 °C. The Tm increased by 2 °C upon binding pyruvate, and by 1 °C upon binding 
α -KPA (Supplementary Figure S6).
Mass spectrometric analysis with MRM. In order to examine the product formation and inhibi-
tion more directly, we carried out LC-MS analyses (Fig. 3). We observed the peak corresponding to THDP 
([M + H+] = 172.4) when α -KPA was absent and in the presence of α -KPA the relative abundance peak corre-
sponding to the mass of THDP was decreased. These results showed inhibition of the THDP product formation 
by α -KPA (Fig. 3A,B). In the MS/MS method, THDP was fragmented into two masses 107.4 and 125.3, as evident 
from a daughter scan corresponding to the parent mass of THDP (Supplementary Figure S7A). The negative con-
trol experiment in the absence of ASA did not show any peak corresponding to the THDP mass (Supplementary 
Figure S7B).
Further, we quantitated the mass of the THDP product using multiple reactions monitoring (MRM) which 
specifically analyzed the given masses of precursor ion 172.3 and the product ions 125.3 and 107.4 by computing 
the SRM peak area of the UPLC chromatogram (Supplementary Figure S7C,D). We obtained a large peak area for 
the THDP product when α -KPA was absent whereas the SRM peak area was reduced by 50% in the presence of 
α -KPA on account of inhibition of the THDP product formation by α -KPA.
Mtb-rDapA oligomerization. The native Mtb-rDapA formed a tight tetramer in solution with a molecular 
weight corresponding to 144 kDa. The monomer peak could not be observed (Fig. 4A). Mtb-rDapA was also 
studied in the presence α -KPA at ratios of 1:5, 1:10 and 1:50 molar excess (Fig. 4A) incubated at 37 °C for 5 min. 
We did not obtain any peak corresponding to either the tetramer or the octamer of Mtb-rDapA when α -KPA was 
present in 50-fold molar excess. Only a strong peak corresponding to the α -KPA was observed (Fig. 4). However 
at ratios of 1:5 and 1:10 of Mtb-rDapA to α -KPA the oligomerization was not affected (Supplementary Figure 
S8A,B). These results show that in the presence of the inhibitor α -KPA, Mtb-rDapA is unable to form oligomers 
and this disruption explains the absence of the enzyme activity (Fig. 4A). These observations are also supported 
by co-crystal structure data, which showed only monomers.
Docking and Molecular Dynamics Simulation of Mtb-DapA. The crystal structure of native 
Mtb-DapA (PDB ID: 1XXX)11 was used as a template and molecular docking with ligands were carried out with 
Data collection statistics
 Wavelength (Å) 1.5418
 Resolution (Å) 2.40 (2.53–2.40)a
 Space group P42212
 Cell dimensions (Å) a = b = 84.78, c = 83.92
 Rmerge (%)b 10.6 (42.0)
 Total number of observations 83110 (9752)
 Total number of unique observations 12296 (1718)
 Mean I/σ I 13.7 (3.9)
 Completeness (%) 98.8 (97.3)
 Multiplicity 6.8 (5.7)
Refinement statistics
 Rwork (%)c 19.78
 Rfree (%)d 25.39
 Number of residues 299
 Number of water molecules 97
 Ligands 1
 RMSD bond length (Å) 0.002
 RMSD bond angle (o) 0.57
Ramachandran statistics 
 Preferred regions (%) 97.3
 Allowed regions (%) 2.7
 Outliers (%) 0
Table 3.  Co-Crystal Data collection, processing and refinement statistics. aValues for outer shells are given 
in parenthesis. bRmerge = Σ j|< I> − Ij|/Σ < I> where Ij is the intensity of the jth reflection and < I> is the average 
intensity. cRwork = Σ hkl|Fo − Fc|/Σ hkl|Fo|. dRfree was calculated as for Rwork but on 5% of the data excluded from the 
refinement calculation.
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Autodock VINA33. The binding free energy of the substrate pyruvate, α -KPA and other ligands upon binding to 
the Mtb-DapA active site were estimated. The docked poses and lowest binding free energy for each of the ligands 
were evaluated. Among the docked ligands, binding of α -KPA (− 5.1 kcal/mol) and pyruvate (− 2.8 kcal/mol) 
were observed to be consistent within the active site of Mtb-DapA. The hydrogen bond network at the active site 
residues of Mtb-DapA docked with α -KPA and pyruvate are shown in Fig. 5A–D.
In order to examine the overall stability of the binding mode we carried out molecular dynamics (MD) simu-
lations of the docked complexes (1) Mtb-DapA + α -KPA and (2) Mtb-DapA + Pyruvate. Initial simulation exper-
iments showed that the ligand α -KPA drifted away from the active site pocket within 1 ns and never returned to 
the active site over the 100 ns simulation, in contrast to pyruvate, which remained bound throughout. Therefore, 
in the case of α -KPA we repeated simulations using the co-crystal complex.
We performed MD simulations of α -KPA and pyruvate-docked to Mtb-rDapA using GROMOS 53 force field 
up to 500 ns. The stability and per-residue fluctuations were monitored by calculating root mean square deviation 
(RMSD) of the MD trajectory. As depicted in Fig. 5E, the RMSD of both the docked complexes increased initially 
due to the relaxation of the structure from the starting conformation and both models were stabilized during 
the entire simulation time. The RMSD of all the backbone atoms of α -KPA-docked Mtb-rDapA (black contour) 
reached a plateau after 40 ns whereas the RMSD of all the backbone atoms of pyruvate-docked Mtb-DapA (red 
contour) reached a plateau after 90 ns (Fig. 5E).
To identify the regions of higher flexibility, the per residue root mean square fluctuation (RMSF) was calcu-
lated during the last 400 ns (Fig. 5F). The RMSF of the α -KPA-bound Mtb-rDapA is shown in the black contour, 
whereas that of the pyruvate bound model is shown in the red contour.
As is evident, the RMSF of the N-terminal regions, encompassing amino acid residues 20–30, 80–102, and 
172–185, exhibited high fluctuation, ranging from 0.38 nm to 0.7 nm in the pyruvate-Mtb-DapA complex com-
pared to the α -KPA-bound complex. On the other hand, Arg123 in the N-terminal half and the entire α -helix 
portion of the C-terminal region, encompassing amino acid residues 200–300, were observed to be highly fluc-
tuating (up to 0.7 nm) in the α -KPA-bound complex (black contour) compared to the pyruvate-docked complex 
Figure 3. Mass spectral analysis of the reaction mix of Mtb-rDapA and Mtb-rDapB coupled assay mix. 
(A) MS analysis of the Ultra Performance Liquid Chromatography (UPLC)-separated peak (encircled) 
corresponding to THDP. (B) Coupled assay mixture prepared for MS analysis with addition of α -KPA and 
subjected to UPLC. Small peak (marked arrow) corresponding to THDP mass of 172 was observed.
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Figure 4. Size exclusion chromatograms of purified Mtb-rDapA. (A) Size exclusion chromatogram  
showed the elution peak of α -KPA in the range 18 to 20 ml fraction (green line). Mtb-rDapA incubated with  
α -KPA (1:50 ratio) at 37 °C for 5 min resulted in two peaks one at 8 to10 ml elution fraction corresponding to  
Mtb-rDapA aggregates (blue line) and second one at 19 to 22 ml fraction corresponding to α -KPA (blue line). 
Mtb-rDapA itself exhibited a peak at 13.4 ml (144 kDa) that corresponds to the tetramer of Mtb-rDapA tetramer 
(pink line). (B) Calibration curve for the size exclusion chromatogram using molecular weight standards 
proteins, namely, Apoferritin (443 kDa), β -Amylase (200 kDa), Alcohol dehydrogenase (150 kDa), BSA 
(66 kDa), carbonic anhydrase (29 kDa), cytochrome C (12.4 kDa).
Figure 5. A close view of active site region of Mtb-DapA docked with pyruvate and α-KPA. For docked α 
-KPA-Mtb-rDapA complex, the starting atom coordinates were taken from the co-crystal structure. (A) The 
H-bond network of α -KPA derived from Molecular Docking with Mtb-rDapA as the template is shown with 
active site residues. (B) Docked complex with substrate pyruvate. (C) The molecular surface of Mtb-rDapA 
showing the orientation of α -KPA (D) orientation of substrate pyruvate. (E) Cα backbone RMSD plots of MD 
simulation of ligand-Mtb-DapA. The α -KPA Mtb-rDapA complex is shown in black contour and pyruvate Mtb-
rDapA complex is shown in red contour. X-axis shows the simulation time in picoseconds and y-axis shows the 
backbone RMSD in nanometers. (F) Root mean square fluctuation (RMSF) of amino acid residues of inhibitor 
Mtb-rDapA complex: α -KPA Mtb-rDapA complex RMSF plot is shown as black trace and pyruvate-Mtb-DapA 
complex RMSF plot is shown as red trace. (G) Plots representing the formation of hydrogen bonds between 
the ligands and Mtb-rDapA during the entire simulation: α -KPA-Mtb-rDapA complex is shown in black lines, 
pyruvate-Mtb-DapA complex is shown in red lines.
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(red contour). Interestingly, perhaps due to hydrogen bond formation of the ligand (α -KPA or pyruvate) with 
the active site residues Thr54, Thr55, Tyr143, Arg148 and Lys171, these residues were not fluctuating. It is clearly 
evident from the differences in the RMSF of the amino acid residues of two cases that, even though α -KPA and 
pyruvate bind in the active site region of Mtb-DapA, the molecular dynamics results show significant differences 
in the interactive modes between the two ligands.
The hydrogen bonding patterns between ligands and Mtb-DapA or Mtb-rDapA during simulations suggest 
(Fig. 5G) that pyruvate maintains stable hydrogen bonding with the active site residues throughout the simu-
lation, in contrast to α -KPA. Although the two simulations are not strictly comparable, these results offer an 
approximate view of the differences between the binding properties of the two ligands. Likewise, in the case of 
structural analogues of α -KPA, only the α -hydroxyl pimelic acid showed consistent hydrogen bond during sim-
ulation (Supplementary Figure S9).
Discussion
Previous studies of the co-crystal structure of Escherichia coli DapA complex with the inhibitor alpha-ketopimelic 
acid (α -KPA) had shown that α -KPA interacts with the pyruvate binding site8. We obtained a similar result, 
thereby validating α -KPA as an inhibitor candidate for Mtb-rDapA.
In order to test the role of the different moieties of α -KPA, considering α -KPA as the base inhibitor, we 
designed several analogues, either varying the chain length or eliminating the α -keto group. We observed that 
the α -keto group is essential for inhibition. Shortening the chain length even by one carbon atom decreases 
the maximal inhibition drastically up to 50%, even with retention of the α -keto group. Compounds containing 
aromatic groups had no observable inhibition of Mtb-rDapA (Table 1). Similarly, the substitutions of an amide 
or ester at the carboxylic acid end of α -KPA could not improve the inhibition compared with α -KPA. However, 
replacement of the keto group with a hydroxyl moiety achieved inhibition comparable with α -KPA (Table 1). It is 
noteworthy that for the similar molecular weight range, the topological polar surface area 91.7 Å2 plays a cardinal 
role in inhibition.
The IC50 of α -KPA did not remain constant at varying pyruvate concentrations (0.17–1 mM) although in the 
initial 30 minutes it is stable. These experiments showed that with time the IC50 increased up to 2 fold showing 
that the binding of the α -KPA with Mtb-rDapA, although stable, can be overcome by competition over time or 
by increasing concentrations of pyruvate. In the case of pyruvate, the Schiff base condensation with pyruvate 
could pull the equilibrium towards the Mtb-rDapA pyruvate complex. As in the case of E. coli, in Mtb-rDapA, 
α -KPA binds in the same active site as pyruvate. These data are supported by co-crystal structure data as well. 
Direct examination of inhibition of THDP product formation by LC-MS analysis, showed up to 50% reduction in 
area under the curve (AUC) inhibition at 1 mM KPA (saturating concentration) by multiple reaction monitoring 
analyses (Fig. 3D,E). Most DapA enzymes from bacteria have been shown to exist as homotetramers and such 
a quaternary structure appears to be required for the enzyme activity11. Our results show that α -KPA disrupts 
the oligomerization of Mtb-rDapA thereby causing loss of enzyme activity. Thus, the paradigm of disruption of 
tetramer structure of DapA underlying inhibition of enzyme activity is evident from these results.
Molecular dynamics simulations over 500 ns showed that pyruvate was consistently bound to the active site 
showing stable binding through hydrogen bonds throughout the entire simulation whereas α -KPA exhibited 
a less stable binding mode (Supplementary Figures S10 and S11). These data indicate that α -KPA binding to 
the enzyme requires a specific stereo-chemical orientation in order to achieve maximum and stable binding. 
Therefore ligands with specific stereo chemically locked conformation to bind to active site could be preferred 
inhibitors.
Published reports on the emergence of Mtb resistant to first and second line drugs including isoniazid, 
rifampicin, pyrazinamide, ethambutol, streptomycin, cycloserine, and moxifloxacin highlight the complexity of 
current TB drug regimens. Some of these drugs increased the risk of hepatotoxicity, fever, nausea and skin rashes. 
We hope that our report describing a new set of inhibitors could aid the discovery pipeline of new TB drugs34.
Conclusions
1. α -ketodicarboxylic acid of chain length (7 carbons) is an inhibitor of Mtb-rDapA.
2. The substitution of amide or ester at the carboxylic acid end inhibited the enzyme in the range of 45–65%.
3. Contraction and extension of the carbon chain length with inclusion of other substituents did not preserve 
or improve inhibition.
4. The α -keto group is essential to achieve maximal inhibition. This group can be reduced to hydroxyl.
5. α -KPA binds to the substrate (pyruvate) binding site.
6. This competitive binding is supported by co-crystal structure data.
7. Inhibition is achieved by disruption of the tetrameric structure of Mtb-rDapA.
Methods
Cloning, expression and purification of DapA. Polymerase chain reaction (PCR) amplification 
and cloning. The Mtb-dapA and dapB open reading frames were cloned in the expression vector pET28a 
(Novagen, USA) for expression as N-terminal 6x His-tagged proteins. The genomic DNA of M. tuberculosis  
H37Rv was used as the template in the PCR amplification using the following primers: Forward primer 
for dapA 5′ -AACCTTGGGATCCGTGACCACC–3′ and Reverse primer was 5′ -GGGAAGGTCTCGA 
GCCACTTCTGGG-3′. forward primer for dapB was 5′-GTCTAGGGGATCCGCCATGCGGGTA-3′ and the 
reverse primer 5′ -TGAACGCGATTAT CAACTCGAGATACAGG-3′ . In both cases the restriction sites BamHI 
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and XhoI were added in the forward and in the reverse primer respectively. The PCR conditions were initial 
denaturation step of 5 min at 95 °C followed by 30 cycles of 30 sec at 95 °C, 45 sec at 53 °C (for dapA) or 59 °C 
(for dapB), 90 sec at 72 °C and a final extension step of 10 min at 72 °C, using Taq DNA polymerase (Bangalore 
Genei, India). The PCR product was gel eluted and purified using DNA isolation kit (Qiagen, Germany). PCR 
products were double digested with the restriction enzymes BamHI and XhoI and then cloned in frame in pET28a 
predigested with the same restriction endonucleases (New England Biolabs (NEB), USA) ligated using T4 DNA 
ligase (NEB, USA). Recombinant plasmids were transformed in to E. coli DH5α , selected by colony PCR screen-
ing and confirmed by sequencing.
Over-expression and purification of recombinant protein. To over-express the fusion constructs, plas-
mids were transformed into E. coli BL21(DE3) (Invitrogen, USA) and transformants were grown at 37 °C in 
Luria Bertani Broth (Himedia Laboratories, India) containing 50 μ g/ml Kanamycin. At an optical den-
sity of 600 nm (OD600) of 0.6, the culture was cooled to 16 °C in ice water for 1 hour, induced by adding 
Isopropyl-D-thio-β -galactopyranoside (IPTG; Sigma, USA) to a final concentration of 0.25 mM and incuba-
tion was continued with shaking (220 rpm) for 16 hours at 16 °C. The cells were harvested by centrifugation at 
6800 × g for 10 min at 4 °C. The pellet was resuspended in 10 ml of lysis [20 mM Tris-HCL, pH 7.9, 500 mM NaCl, 
10 mM imidazole, 5% (v/v) glycerol, 2 mM β -mercaptoethanol, 1 mM phenyl methyl sulfonyl fluoride (PMSF; 
Sigma-Aldrich, USA)].
Lysozyme (Hen egg white, Sigma, USA) was added in the suspension to final concentration of 1 mg/ml 
and incubated for 1 hour on ice. Cells were lysed by sonication (Sonic Vibra-Cell) with 30 cycles of 30 s pulse 
and 20 s rest on ice followed by centrifugation at 29000 × g for 30 min at 4 °C. Expressed proteins (Mtb-rDapA 
and Mtb-rDapB) were found to be soluble by analyzing supernatant and pellet fractions on 12% SDS-PAGE 
(Laemmli, U.K. 1970). Purification of 6x His-tagged proteins, Mtb-rDapA and Mtb-rDapB, were carried out by 
affinity chromatography using Nickel-Nitrilotriacetate (Ni-NTA) resin column (Qiagen, Germany). The soluble 
fraction was incubated with 1 ml of Ni-NTA resin pre-equilibrated with equilibration buffer (20 mM Tris-HCl, 
pH 7.9, 500 mM NaCl) overnight at 4 °C. The supernatant was loaded on to the column and washed with 10 
column volumes of wash buffer-1 (20 mM Tris-HCl, pH 7.9, 500 mM NaCl, 5 mM imidazole, 5% (v/v) glyc-
erol, 2 mM β -mercaptoethanol), 25 column volumes of wash buffer-2 (20 mM Tris-HCl, pH 7.9, 500 mM NaCl, 
20 mM imidazole, 5% (v/v) glycerol, 2 mM β -mercaptoethanol), five column volumes of wash buffer-3 (20 mM 
Tris-HCl, pH 7.9, 500 mM NaCl, 50 mM imidazole, 5% (v/v) glycerol, 2 mM β -mercaptoethanol), five column 
volumes of wash buffer-4 (20 mM Tris-HCl, pH 7.9, 500 mM NaCl, 100 mM imidazole, 5% (v/v) glycerol, 2 mM 
β -mercaptoethanol).
Elution of bound proteins were carried out with elution buffer (20 mM Tris-HCl, pH 7.9, 500 mM NaCl, 
250 mM imidazole, 5% (v/v) glycerol, 2 mM β -mercaptoethanol). The fractions containing significant amount of 
purified Mtb-rDapA or Mtb-rDapB as observed by SDS-PAGE (12%) analysis were pooled and dialyzed against 
20 mM Tris-HCl, pH 7.9, 500 mM NaCl, 5% (v/v) glycerol using dialysis membrane (3.5K MWCO, ThermoFisher 
SCIENTIFIC, USA) at 4 °C overnight and concentrated using Amicon ultra concentrator-15 (3 kDa NMWL) 
(Millipore, USA), and stored at 4 °C. The concentrations of recombinant proteins were estimated by Bradford 
method (Bio-Rad Laboratories, USA) using known concentration of BSA (Sigma-Aldrich, USA) as standard.
Western Blotting and MALDI-TOF analysis. Purified Mtb-rDapA and Mtb-rDapB proteins were elec-
trophoresed on SDS-PAGE (12%) at 100 V, 90 mA for 3–4 hours in Mini-PROTEIN Tetra Cell (Bio-Rad, USA) 
at room temperature. For size determination, Pre-stained molecular weight standards (10–170 kDa) (Fermentas, 
Canada) was used. Transfer of proteins from SDS-PAGE to nitrocellulose membrane (Bio-Rad, USA) was carried 
out using a TransBlot apparatus (Bio-Rad, USA) in the transfer buffer (24 mM Tris-HCl pH 8.0, 192 mM glycine 
and 20% methanol) for 2 hours at 90 V at 4 °C35. Ponceau S (Sigma, USA) dye at final concentration (0.1%) was 
used to confirm transfer. After washing the Ponceau S stain using PBS buffer (137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4, and 1.47 mM KH2PO4) the blot was incubated in blocking buffer containing 5% Skimmed milk pow-
der (Sigma, USA) for 2 hours at room temperature. Blots were washed twice with PBS-T (PBS + 0.2% Tween-20) 
and PBS, and were incubated with horseradish peroxidase (HRP) conjugated anti-Histidine antibodies (Qiagen, 
Germany) at 1:5000 dilution for 2 hours at room temperature. Finally, the blot was washed twice with PBS-T and 
PBS. The blot was developed using 0.05% of 3, 3′ -Diaminobenzidine (DAB) (Sigma, USA) (Supplementary Figure 
S12).
In order to further confirm identity of purified recombinant proteins, peptide mass fingerprinting was carried 
out using trypsin and the tryptic digested peptides. The ‘mass spectra’ were searched using MASCOT search 
engine against MSDB (mass spectrometry protein sequence Database)36.
Coupled enzymatic activity assay. The purified N-terminal 6x His-tagged Mtb-rDapA and Mtb-rDapB 
proteins were used to prepare the coupled enzyme assays (Supplementary Figure S12). The coupled enzyme assay 
was used to investigate the kinetics of Mtb-rDapA. The formation of dihydrodipicolinate by Mtb-rDapA was 
measured by reduction to tetrahydrodipicolinate by Mtb-rDapB using NADPH as electron donor. The consump-
tion of NADPH can be measured spectrophotometrically at 334 nm. The following components were prepared 
fresh in each experiment at final concentration: pyruvate (500 μ M), Aspartate semi aldehyde [(S)-ASA] (400 μ M) 
and NADPH (160 μ M). (S)-ASA in isolated form is unstable except in aqueous strong acid. Therefore we synthe-
sized the precursor of (S)-ASA known as compound 7 (tert-butyl derivative)37 commercially, which was of high 
quality (> 95%) as judged by 1H-NMR. Just before the assay, compound 7 was deprotected using trifluoroacetic 
acid and solvent 1,2-dichloroethane (1:1 v/v) and stored on ice37. The standard assay for Mtb-rDapA activity was 
performed in 50 mM sodium phosphate buffer pH 7.4 containing NADPH (160 μ M), Mtb-rDapA (0.2 μ g/ml, 
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36 nM) and Mtb-rDapB (3 μ g/ml, 0.58 μ M). The concentration of pyruvate was varied from 170 μ M to 2000 μ M 
and readings were taken in triplicate and the experiments were repeated until consistent kinetics was obtained. 
Similarly the concentration of substrate ASA was varied from 35 μ M to 4000 μ M until consistent kinetics was 
obtained.
Assay mix (92 μ l) was added to each well in a 96 well plate (Tarson, India) and incubated at 37 °C for 5 min. 
The reaction was started by the addition of the (S)-ASA (8 μ l). The absorbance at 340 nm was measured at 37 °C 
(Infinite200PRO spectrophotometer, TECAN, Europe) over a time period of 600s (10 min). Water was used as 
blank and the negative control contained assay mixture without (S)-ASA. Decrease in absorption commensu-
rate with decreasing concentration of NADPH corresponded to the consumption of substrate, or equivalently, 
formation of product. The Mtb-rDapB was 16 times in molar excess to ensure complete consumption of dihy-
drodipicolinate formed. All kinetics measurements were performed in triplicate in 96 well plates (Tarson, India), 
and all experiments were repeated several times to ensure that reproducible results were obtained. Percentage of 
inhibition was calculated from the formula, % of inhibition = ([(Acontrol − Atest)/Acontrol]) × 100, where Acontrol is the 
absorbance of the control sample and Atest is the absorbance of the test sample. The IC50 was calculated using nls 
package in R to the Michaelis–Menten type equation by formula, V2 ~ a* V1/(b + V1), where V2 = % Inhibition, 
V1 = Inhibitor Concentration, a = Maximum Inhibition, b = IC50 (Inhibitor Concentration at half Inhibition). In 
the pre-incubation experiments, initially Mtb-rDapA was pre-incubated at 37 °C for 5 min with varying concen-
trations of the inhibitors. At predetermined time intervals, aliquots were transferred to the standard assay mixture 
and assayed for enzyme activity.
Thus, the activity was measured by following the decrease in absorbance at 340 nm corresponding to the 
oxidation of NADPH to NADP+. This is easily quantifiable because, while NADPH has a strong absorbance 
at 340 nm (the extinction coefficient, ϵ 340′ is 6.3 × 103 M−1cm−1) NADP+ exhibits negligible absorbance at this 
wavelength. This assay is able to measure DapA (Mtb-rDapA) kinetics if DapB (Mtb-rDapB) is present in excess, 
because under these conditions DapA becomes rate limiting.
Selection of compounds and their synthesis for inhibition studies. In this work we tested struc-
tural analogues of pyruvate, namely, α -KPA, α -ketoglutaric acid, α - ketoadipic acid Pimelic acid, Benzoic acid, 
Fusaric acid, p-amino Benzoic acid, Methyl butyrylacetate, p-aminosalicylic acid and Phenoxyacetic acid. Various 
concentrations (0.125 mM, 0.25 mM, 0.5 mM and 1 mM) of these water soluble compounds were used to test the 
extent of inhibition.
The α -KPA analogues were prepared mainly with substitutions of Amide (C= ONH2), Amine (R-NH2), Ester 
(R-COOR), Sulfonamides (S-CONH2), Sulfoxide (R-S= OR’), Sulfone group (R-SOOR), hydroxyl group (-OH) 
and aromatic rings, namely, phenyl, benzene, imidazole. The solid state compounds having molecular weight in 
the range of 174–237 Da were 90–97% pure as measured by LC-MS data.
In this study the inhibition of Mtb-DapA were tested with 29 structural analogues of α -KPA as listed in the 
Table 1. 23 were soluble in 100% methanol and rests were soluble in water at 1 mg/ml. We tested inhibition char-
acteristics of the compounds in the concentration ranges of 10 μ M, 50 μ M, 100 μ M, 200 μ M and 250 μ M.
Crystallization, data collection and structure solution. Mtb-rDapA (6 mg/ml) was incubated with 
α -ketopimelic acid at two different Mtb-rDapA: α -ketopimelic acid molar ratios (1:10; 1:50) for 2–3 hours at 4 °C. 
Post incubation, the sample was centrifuged at 6800 × g for 20 minutes. Initial crystallization experiments with 
the incubated mixture were performed using crystallization screens (Hampton Research, Inc.). Crystallization 
trials were performed using both the micro-batch method and hanging drop vapour diffusion methods of crys-
tallization. Plate like, poorly diffracting crystals were obtained in the condition: 1.4 M Sodium Citrate Dihydrate, 
0.1 M HEPES, pH 7.5 within three weeks of setting up the crystallization experiment. Optimization by varying 
the concentrations of the components in crystallization condition resulted in single large crystals in the condi-
tion containing 1.34 M tri-sodium citrate, 0.1 M Tris-HCl, pH 7.5 at 1:10 of Mtb-rDapA to α -ketopimelic acid 
ratio (Supplementary Figure S13). Data was collected on one such crystal on a MAR345 image plate mounted 
on a Rigaku MicroMax007HF rotating-anode X-ray generator. The data were integrated using iMOSFLM38 and 
scaled using SCALA39. The phase information was obtained by Molecular Replacement method using PHASER40  
(M. tuberculosis DapA, PDB: 1XXX was used as a search model)11. The model was built using COOT41 and 
refined using Refmac5 from the CCP4 suite of programs42. The ligand was incorporated into the model at the final 
stages of refinement. The library files for α -ketopimelic acid were obtained from the PRODRG server (davapc1.
bioch.dundee.ac.uk/prodrg). The data collection and refinement statistics are presented in Table 3. Furthermore, 
we have deposited and validated the PDB in RCSB protein data bank and the given PDB ID is 5J5D.
Thermal shift assay for inhibitor screening. The fluorescence based thermal shift assay for screening 
of identified ligands, which is based on the principle that ligand binding alters thermal stability of protein. This 
method allows us to monitor the protein denaturation upon heating using fluorescence based dye (Sypro orange, 
Sigma, USA), which binds to hydrophobic part of proteins during protein denaturation and emits fluorescence at 
580 nm43. We can monitor the changes in fluorescence and generate a thermal melting curve using real time PCR. 
The mid-point of the melting curve designated as the melting temperature Tm corresponding to 50% of protein 
being denatured.
The thermal shift assay was carried out in the LightCyclerR LC480 qPCR machine using 384 well PCR plates 
(Roche, USA). An assay mixture of 20 μ l contained 20 μ M Mtb-rDapA, 15 X Sypro Orange (Sigma), 50 mM 
sodium phosphate buffer pH 7.4 and ligand in the range 0.2 mM to 1 mM. The ligands and Mtb-rDapA were 
diluted in sodium phosphate buffer. The PCR plates were sealed with optical seal, mixed well and centrifuged after 
the assay mixture was added. The thermal scanning was started from 20 °C to 95 °C at a heating rate of 0.5 °C/min. 
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The fluorescence intensity was measured by excitation at 465 nm and emission at 580 nm. Curve fitting, melting 
temperature calculation and report generation on the raw Fluorescence based thermal shift assay (FTS) data were 
performed using pre-installed analysis software provided with the instrument (Roche, USA)44.
LC/MS analysis of 2,3,4,5-tetrahydrodipicolinic acid (THDP), product of the coupled assay. 
The activity of Mtb-rDapA and Mtb-rDapB in catalyzing formation of THDP was confirmed by LC/MS analysis. 
A reaction mixture contained 1 μ g of Mtb-rDapA, 30 μ g of Mtb-rDapB, 10 mM pyruvate, 1 mM ASA, 0.16 mM 
NADPH and 50 mM sodium phosphate buffer pH 7.4 run at 37 °C for 5 min using UV-Vis spectrophotometer 
for THDP formation. Mtb-rDapA and Mtb-rDapB were then inactivated at 55 °C for 5 min to preserve integrity 
of reaction products and reaction mixture passed through 10 kDa cutoff filter unit (Millipore, USA) to filter the 
proteins and centrifuged at 6800 × g. The flow-through containing reaction products was used in LC/MS anal-
ysis. In order to observe the effect of inhibitor on THDP formation we added α -KPA in the assay mixture. The 
sample was subjected to analysis on a LC/ESI-MS (Quattro Micro API, Waters) coupled to a UPLC inlet. The flow 
through was loaded onto an Acquity UPLC BEH shield RP18, 1.7 mm, 2.1 100 mm column comprising a mobile 
phase of buffer A (water, 0.1% formic acid) and buffer B (acetonitrile, 0.1% formic acid) at a flow rate of 0.2 ml 
min−1. The same protocol was followed without ASA as a negative control and subjected to LC/MS analysis. The 
mobile phase gradient program started at 100% of buffer A then decreased to 25% at 6.0 min and held for 7th 
min, reversed the gradient for 8 min to 100% of buffer A. The mobile phase returned to the initial composition 
at 8.0 min and equilibrated before the next injection. Electrospray ionisation was performed in the positive ion 
mode with the following parameters: capillary voltage 3.5 KV, cone voltage 35 V, desolvation temperature 350 °C, 
nebuliser gas (N2) 750 L/hr. For fragmentation of THDP the collision gas (Ar) was used with collision energy 
25 eV. Quantitative analysis of THDP formation was carried out by assessment of peak area in multiple reactions 
monitoring (MRM) mode with precursor ion 172.3 of THDP and corresponding daughter ions 125.6 and 107.5 
by using above mentioned LC-MS/MS parameters.
Size exclusion Chromatography. Prior to gel filtration, the pre-packed Superdex 200 10/300 column 
(GE Healthcare) was pre-equilibrated with 50 mM Tris HCl pH 7.5, 150 mM NaCl and 10% glycerol. 25 μ M 
Mtb-rDapA in 25 mM Tris/150 mM NaCl buffer was loaded in 500 μ l volume. Multiple fractions of 1 ml volume 
were collected and each fraction runs on 12% SDS-PAGE gel electrophoresis. The ligand α -KPA in 1:5, 1:10 and 
1:50 molar ratio of Mtb-rDapA was incubated with Mtb-rDapA and subjected to run as above. The chromato-
grams were collected by measuring absorption at 280 nm as a function of buffer volume at a flow rate of 0.3 ml/min. 
The column was calibrated by passing Apoferritin eluted at 10.5 ml, β -Amylase eluted at 12.5 ml, Alcohol dehy-
drogenase eluted at 13 ml, BSA eluted at 14.5 ml, carbonic anhydrase eluted at 16.9 ml, and cytochrome C eluted 
at 19 ml followed by a standard curve generation.
Docking studies. The initial atom coordinates of Mtb-DapA crystal structure were obtained from the 
RCSB protein data bank (PDB id: 1XXX)11 and used to generate the starting coordinates for the docking study. 
Molecular docking of DapA and its putative inhibitors were carried out using Autodock Vina (version 4.0)33, 
which has significant improvements and average accuracy of the binding mode prediction compared to other 
docking algorithms33 and also allows flexibility in the ligand.
The docking parameters include ligand and receptor preparation involving addition of hydrogen atoms, 
merging non-polar hydrogen atoms, rotatable torsion bond followed by grid construction with volume of 
22 Å × 24 Å × 26 Å spacing of 0.375 Å centered on the receptor active site amino acid residue Cα of LYS 171, 
x = 9.785, y = 42.020, z = 69.219. All the compounds were screened on the basis of binding energy and hydrogen 
bonding with active site residues of Mtb-rDapA. Among the active site residues, Thr54, Thr55 and Tyr143 showed 
interaction with these compounds through hydrogen bonding.
Molecular Dynamics Simulation. The best fitting conformation of Mtb-DapA or Mtb-rDapA and its 
ligand (pyruvate or α -kpa) complex obtained from the docking study was further examined using molecular 
dynamics (MD) simulation to examine the stability of Mtb-DapA and ligand interaction. MD simulation was car-
ried out using GROMOS53a6.ff all atom force field in GROMACS version 4.5.445,46 with explicit solvent and under 
periodic boundary conditions. GROMOS topology file for ligand was obtained from PRODRG (version 2.5)47. 
The starting coordinates of DapA-ligand complex was neutralized with 7 sodium ions and wrapped up in a peri-
odic box of TIP3P water model that was extended to 10 Å from the solvent. The Particle Mesh Ewald method 
was used to treat the long-range electrostatics48 during the MD simulation. The bond lengths within the protein 
were constrained using LINCS algorithm49. Energy minimization was performed using steepest descent method 
(50,000 steps, 100 ps) in order to relax the initial solvent and ion configuration and to eliminate any residual 
strain. To maintain the temperature of the system at a constant value of 300 K, a Berendsen thermostat50 was 
applied. The ligand position and protein were restrained and the solvent and ions around were equilibrated in two 
phase. The first phase was temperature coupling step conducted under the NVT (constant Number of particles, 
Volume, and Temperature) ensemble for 200 ps to stabilize the temperature of the system at a constant temper-
ature of 300 K. Similarly, the second phase was pressure coupling step to equilibrate the pressure under the NPT 
(constant Number of particles, Pressure and Temperature) ensemble for 200 ps at a constant pressure of 1 atm. 
The conformational sampling (MD simulation data collection) was started after the equilibration step at a con-
stant pressure (1 atm) and a temperature (300 K). The time steps of 2 ps were used to collect the MD simulation 
trajectory.
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Molecular Dynamics trajectory analysis. Root mean square deviation (RMSD) and root mean square 
fluctuation (RMSF) were calculated by using GROMACS MD simulation package (g_rms and g_rmsf) tools. 
The RMSD is calculated for every snapshot collected as function of simulation time. In this study RMSD was 
computed for the backbone atoms of the protein and the ligand, taking the starting coordinates as the reference 
structure. The RMSF is a measure of the flexibility calculated as the square root of the variance of the fluctuation 
around the average position for backbone atom of each residue. Details of H-bond interactions between the 
ligand and the protein were examined using g_hbond module in GROMACS.
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